CL2009001511A1 - Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients. - Google Patents

Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.

Info

Publication number
CL2009001511A1
CL2009001511A1 CL2009001511A CL2009001511A CL2009001511A1 CL 2009001511 A1 CL2009001511 A1 CL 2009001511A1 CL 2009001511 A CL2009001511 A CL 2009001511A CL 2009001511 A CL2009001511 A CL 2009001511A CL 2009001511 A1 CL2009001511 A1 CL 2009001511A1
Authority
CL
Chile
Prior art keywords
prevention
immune response
pharmaceutical formulation
lpv
lpm
Prior art date
Application number
CL2009001511A
Other languages
Spanish (es)
Inventor
Castro Inostroza Erica
Gonzalez Riquelme Margarita
Aeschlimann Arjona Valeska
Borquez Yanez Rodrigo
Original Assignee
Univ De Concepcion 61 02%
Laboratorio Pasteur 9 44%
Duraplast Ltda 22 99%
Servicio Salud Concepcion 6 55%
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ De Concepcion 61 02%, Laboratorio Pasteur 9 44%, Duraplast Ltda 22 99%, Servicio Salud Concepcion 6 55% filed Critical Univ De Concepcion 61 02%
Priority to CL2009001511A priority Critical patent/CL2009001511A1/en
Publication of CL2009001511A1 publication Critical patent/CL2009001511A1/en
Priority to PCT/CL2010/000026 priority patent/WO2011000124A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulación farmacéutica a base de cepas probioticas, que comprende una biomasa seca de cepas viables probioticas de lactobacillus spp, opcionalmente excipientes y coadyuvantes; uso de dicha formulación para la prevención y recuperación deinfecciones urinarias y reactivación de la respuesta inmune.Pharmaceutical formulation based on probiotic strains, comprising a dry biomass of viable probiotic strains of lactobacillus spp, optionally excipients and adjuvants; use of said formulation for the prevention and recovery of urinary infections and reactivation of the immune response.

CL2009001511A 2009-07-02 2009-07-02 Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients. CL2009001511A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2009001511A CL2009001511A1 (en) 2009-07-02 2009-07-02 Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.
PCT/CL2010/000026 WO2011000124A1 (en) 2009-07-02 2010-07-02 Pharmaceutical composition including viable probiotic strains of lactobacillus spp. used for the prevention and recovery of individuals with urinary tract infections and immunocompromised individuals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2009001511A CL2009001511A1 (en) 2009-07-02 2009-07-02 Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.

Publications (1)

Publication Number Publication Date
CL2009001511A1 true CL2009001511A1 (en) 2009-10-23

Family

ID=43410428

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001511A CL2009001511A1 (en) 2009-07-02 2009-07-02 Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.

Country Status (2)

Country Link
CL (1) CL2009001511A1 (en)
WO (1) WO2011000124A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627984T3 (en) * 2012-09-14 2017-08-01 Claride Pharma S.R.L. Composition for the prevention and treatment of acute and recurrent urinary tract infections
CL2017001273A1 (en) * 2017-05-17 2018-03-16 Univ San Sebastian Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283027T3 (en) * 1996-11-29 2007-10-16 Bio K + International Inc. LACTIC FERMENT THAT INCLUDES A PARTICULAR CEPA OF LACTOBACILUS ACIDOFILUS AND USE OF THE SAME.
US20130011374A1 (en) * 2006-12-22 2013-01-10 Bio-K Plus International Inc. Growth inhibition of microorganisms by lactic acid bacteria
WO2009068474A1 (en) * 2007-11-29 2009-06-04 Carinsa. Creaciones Aromáticas Industriales, S. A. Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect

Also Published As

Publication number Publication date
WO2011000124A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
ES2477882T3 (en) Probiotics, secretory IgA and infection
ES2524432T3 (en) Lactic acid bacteria such as probiotic strains and compositions containing the same
PE20190417A1 (en) USE OF PROBIOTICS IN THE TREATMENT AND / OR PREVENTION OF ATOPIC DERMATITIS
ES2561253T3 (en) Probiotic bacteria that have antioxidant activity and use thereof
EP4257194A3 (en) Use of microbial communities for human and animal health
MY146590A (en) Probiotic bifidobacterium strains
CL2012000869A1 (en) Composition comprising selected strain of lactobacillus plantarum cect 7527, or mutant strains thereof; use of a composition to prevent and / or treat cardiovascular disorders.
ATE526836T1 (en) NUTRIENT COMPOSITION WITH PROBIOTICS
MX2012005524A (en) Probiotic bifidobacterium strain.
PL406050A1 (en) New strain of Bifidobacterium breve
PH12018502042A1 (en) Use of probiotics in the treatment and/or prevention of psoriasis
WO2008117267A3 (en) Probiotic bifidobacterium strains
DE60233326D1 (en) PROBIOTIC STRAINS OF THE GENUS LACTOBACILLUS SALIVARIUS
CL2011000891A1 (en) Use of the probiotic strain lactobacillus reuteri dsm17938 or a nutritional composition comprising a probiotic bacterial strain lactobacillus reuteri dsm17938 because it serves to prepare a medicament or a nutritional composition useful for reducing sleep disturbances and / or improving sleep quality or patterns of I dream in humans or animals.
MX2010000422A (en) Combination of a microorganism and a phytosphingosine derivative, composition, methods of use.
JP2015525780A5 (en)
DK3554517T3 (en) PROBIOTIC COMPOSITION COMPRISING LACTOBACILLUS RHAMNOSUS AND LACTOBACILLUS PARACASEI STRAINS
RS54478B1 (en) Isolated microorganism strain lactobacillus plantarum mcc1 dsm 23881 and its use
PL1796698T3 (en) Strain of lactobacillus acidophilus having analgesic properties in the gastrointestinal system
HK1198326A1 (en) Lactobacillus rhamnosus and bifidobacterium animalis subsp. lactis for use in prevention or treatment of upper respiratory tract infections
CO2017007338A2 (en) Composition comprising two strains of the microbial species lactobacillus rhamnosus and bifidobacterium longum capable of increasing male fertility
CL2009001506A1 (en) Quew
CL2009001511A1 (en) Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.
JP2016003187A5 (en)
AR095486A1 (en) NUTRITIONAL COMPOSITION FOR THE TREATMENT OF CHRONIC IDIOPATHIC EMESIS IN FELINOS AND CANES